First a message from our friends at Porter & CO [ad]
Every investor is chasing the same names...
Nvidia, Palantir, Alphabet, and the rest of the Mag7.
But it doesn't take a genius to know those stocks are trading steeply
And yet, that doesn't mean AI is going away. AI will change everything.
People won't stop using it.
Adoption will continue to accelerate.
The models will get better, faster, and smarter.
So while other investors are attempting to speculate on which startup will emerge victorious or survive the inevitable reset... I don't really care because I'm playing a different game.
You see, in this new era, it's almost impossible to decipher who will be the winners and losers because everything is evolving so rapidly. Instead, I'm betting on what I know for certain.
That's why I'm urging my friends and family to consider AI like this.
Good Investing,
Porter Stansberry
FEATURED ARTICLE
Top 5 “Under-the-Radar” Accumulation Setups (With Near-Term Buy Signals)
When markets get choppy, the best short-term longs often aren’t the headline mega-caps—they’re the names quietly showing institutional accumulation: higher lows, strong relative strength, and volume showing up on up-days.
Below are five stocks where the tape is signaling growing accumulation and the chart is offering actionable, short-term “buy-signal” frameworks (suggestive, not definitive), plus current Street price targets.
1) Hamilton Insurance Group (HG) — Quiet Breakout, Real Fundamental Torque
Why it’s under the radar: HG is a newer public name in specialty insurance/reinsurance—less crowded than tech, but it’s showing breakout behavior while the broader tape has been volatile.
Fundamental snapshot (real numbers)
Reported Q3 EPS $1.32 on $667.7M sales (YoY: +78% profit, +30% revenue).
Analysts have looked for Q4 earnings to triple to $1.07 EPS on $621M revenue.
Pretax margin ~26%, ROE ~18% (IBD-cited metrics).
Technicals: what “accumulation” looks like here
Broke out above a 28.72 buy point with strong institutional buying and an RS line hitting new highs.
Current price: $29.70.
Street targets
MarketBeat consensus: $29.88 (high $34, low $25).
Action plan (2–6 week trader framework)
Preferred entry: constructive pullback that holds the breakout area (think “test and hold” near prior pivot levels) rather than chasing stretched candles.
Risk line: a decisive break back below the breakout zone on expanding volume is your “stand down” signal.
Upside path: if HG holds above the pivot and RS stays strong, the next move tends to be a measured push toward the low-$30s where targets cluster.
2) The Pennant Group (PNTG) — Accumulation Grade “B” + Healthcare Operator Momentum
Why it’s under the radar: It’s a healthcare services operator (not flashy), but institutions often rotate into these during messy markets.
Fundamental snapshot (real numbers)
Q3: earnings +15%, revenue +27% year-over-year.
MarketBeat notes Q3 revenue $229.04M vs. $221.96M consensus; EPS $0.30 vs. $0.29 expected.
Technicals: accumulation + a “repairable” setup
IBD flags an Accumulation/Distribution Rating of B (net institutional demand over ~13 weeks).
Also notes a prior breakout around 30.46 that slipped back—important because failed breakouts often become powerful re-breakouts if price regains the pivot with volume.
Current price: $30.35.
Street targets
Investing.com: average 12-mo target $37.50 (high $40, low $34).
Action plan (2–6 week trader framework)
Trigger to watch: reclaiming and holding above the prior pivot zone (around 30.46) with improving breadth/volume.
If it works: targets imply room toward the mid/high-$30s.
If it doesn’t: repeated rejection near the old breakout level is a “no trade / reduce size” tell.
3) Aurinia Pharmaceuticals (AUPH) — “Base + Catalyst” Biopharma With Defined Levels
Why it’s under the radar: Many traders avoid biopharma due to headline risk—so when a clean base forms, it can move fast because positioning is lighter.
Fundamental snapshot (real numbers)
IBD highlights Wall Street forecasting ~1,854% profit growth in 2025 and +19% in 2026 (projection-driven, so treat as high-variance).
The company’s profile is anchored by Lupkynis plus pipeline development.
Technicals: the setup
Formed a flat base with a 16.54 buy point, and it’s been flirting with resistance around its 50-day.
Current price: $14.44.
Street targets
MarketBeat consensus: $17.25 (high $21, low $15).
IBD cites a target around $18.50.
Action plan (2–6 week trader framework)
Aggressive entry idea: strength through near-term resistance with volume, only if it’s accompanied by broad market stabilization.
Cleaner entry: a break above the 16.54 pivot on convincing volume (classic “confirmation” trade).
Risk rule: biopharma setups require strict sizing—one headline can invalidate any chart.
4) SEI Investments (SEIC) — “Steady Compounder” With Quiet Earnings Power + Re-rating Potential
Why it’s under the radar: It’s not a hype ticker—SEIC is an “asset management infrastructure” business. In uncertain markets, these steady growers often see accumulation as money rotates toward quality earnings.
Fundamental snapshot (real numbers)
From SEI’s Q4 2025 results:
Quarterly revenue $607.9M (YoY +9%)
Operating margin 27%
Q4 diluted EPS $1.38 (YoY +16%)
Full-year EPS $5.63 (YoY +28%)
Zacks also notes EPS and revenue beat dynamics and highlights AUM growth.
Current price: $84.45.
Street targets
MarketBeat consensus: $110.17 (high $117, low $101).
Technicals: what accumulation would look like here
With “steady compounders,” the tell is usually:
higher lows,
repeated support at key moving averages,
and volume spikes on up-days after earnings (institutions building positions).
Given the earnings strength above, the tactical question is whether price can hold post-earnings support and start printing higher highs (confirmation that institutions are accumulating rather than just rebalancing).
Action plan (2–6 week trader framework)
Preferred approach: buy strength after a higher-low forms (avoid catching a falling knife).
Confirmation trigger: break above recent swing highs with volume, then “hold, not fade.”
Target logic: the Street’s target band implies meaningful upside if the market regime improves.
5) Celestica (CLS) — AI Infrastructure “Picks-and-Shovels” With Big Growth + Heavy Volume
Why it’s under the radar: CLS is often mislabeled as “just manufacturing,” but it’s increasingly tied to AI infrastructure demand—less crowded than the mega-cap AI complex, yet still levered to the same spend cycle.
Fundamental snapshot (real numbers)
FY 2025 revenue $12.4B (+28% YoY) and adjusted EPS growth +56% YoY.
Nasdaq recap of Q4: net earnings $267.5M ($2.31/share) vs $151.7M ($1.29/share) prior year; non-GAAP EPS $1.89 vs $1.11.
Current price: $307.53 with notable volume.
Technicals: accumulation read
Post-earnings, the “institutional tell” is whether:
the stock holds the earnings gap/impulse move, and
pullbacks are bought on lighter volume (selling pressure drying up).
CLS has been trading like a name institutions are willing to defend after results—exactly the signature you want in a shaky tape.
Street targets
MarketBeat consensus target: $356.59 (high $440, low $120), indicating wide dispersion (higher volatility / higher uncertainty).
Citi maintained Buy but lowered its target to $338 (recent analyst action).
Action plan (2–6 week trader framework)
Better entry: pullback that respects the post-earnings support zone, then a turn upward on rising volume.
Avoid: chasing after multi-day vertical moves—wait for a “tighten” (volatility compression).
Upside map: Street targets cluster in the mid-$300s, with more bullish cases higher; treat the high target as a scenario, not a promise.
What to Watch This Week (The “Accumulation Checklist”)
If these names are truly being accumulated (not just bouncing), you’ll often see:
Up-days on higher volume than down-days
Higher lows forming near key support
Relative strength improving even when indices chop
Breakouts that hold (not "pop and drop")
If 2–3 of the five start doing that simultaneously, it’s a strong signal that institutions are putting money back to work—often before the indices look “safe.”
Editorial Disclaimer
This commentary is for informational and educational purposes only and does not constitute investment advice. All market strategies involve risk, and past performance is not indicative of future results. Readers should conduct their own analysis or consult a licensed financial professional before making investment decisions.